You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The Korean molecular diagnostics firm, a spinoff from genomic services provider Macrogen, also announced plans for an IPO early next year.
The hybridization-based test may provide better detection of emerging COVID-19 variants of concern, due to a higher tolerance for probe mismatches than in PCR.
The deal to create a comprehensive genomic profiling test for Illumina's NextSeq 550Dx comes months after the instrument received regulatory approval in China.
The firm posted total software-related revenues of $18.6 million, up 1 percent from $18.4 million in Q4 2019.
Adaptive Cofounder and Chief Scientific Officer Harlan Robins compared the launch of the test to the unveiling of the Tesla Roadster electric sports car.
The immune cell sequencing company beat Wall Street estimates on the top line, but missed on the bottom line for both Q4 and full-year 2020.
BioIQ will offer Fulgent's next-generation sequencing-based coronavirus assay on its diagnostic testing platform.
University of Glasgow spinout Gabriel Precision Oncology will contribute a bioinformatics pipeline derived from cancer tissue samples to accelerate MDx adoption.
Molzym said a new analytic platform, called AutoSepT, would enable fast pathogen identification directly from specimens in less than five hours.
The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.